Evidence map›Paper›PMID 29083933›Full record

ArticleCancer biotherapy & radiopharmaceuticals2017

Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma.

Peter L Roberson, Lauren B Smith, Meredith A Morgan, Matthew J Schipper, Scott J Wilderman, Anca M Avram, Mark S Kaminski, Yuni K Dewaraja

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biotherapy & radiopharmaceuticals, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Peter L Roberson1 Department of Radiation Oncology, University of Michigan , Ann Arbor, Michigan.
Lauren B Smith2 Department of Pathology, University of Michigan , Ann Arbor, Michigan.
Meredith A Morgan1 Department of Radiation Oncology, University of Michigan , Ann Arbor, Michigan.
Matthew J Schipper1 Department of Radiation Oncology, University of Michigan , Ann Arbor, Michigan.
Scott J Wilderman3 Department of Radiology, University of Michigan , Ann Arbor, Michigan.
Anca M Avram3 Department of Radiology, University of Michigan , Ann Arbor, Michigan.
Mark S Kaminski4 Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan , Ann Arbor, Michigan.
Yuni K Dewaraja3 Department of Radiology, University of Michigan , Ann Arbor, Michigan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNon-Hodgkin Lymphoma patients respond differently to therapy according to inherent biological variations. Pretherapy biomarkers may improve dose-response prediction. MATERIALS AND

methodsHybrid single-photon emission computed tomography (SPECT)/computed tomography (CT) three-dimensional imaging at multiple time points plus follow-up positron emission tomography (PET)/CT or CT at 2 and 6 months post therapy were used to fit tumor response to combined biological effect and cell clearance models from which three biological effect response parameters (radiosensitivity, cold effect sensitivity, and proliferation potential) were determined per patient. A correlation of biological effect parameters and pretherapy biomarker data (ki67, p53, and phospho-histone H3) allowed a dose-based equivalent biological effect (EBE) to be calculated for each patient.

resultsSignificant correlations were found between biological effect parameters and pretherapy biomarkers. Optimum correlations were found by splitting the patient data according to p53 status. Response correlation of progression free survival (PFS) and EBE were significantly improved compared with PFS and absorbed dose alone.

conclusionsIt is possible and desirable to use pretherapy biomarkers to enhance the predictive potential of dose calculations for patient-specific treatment planning.

Indexed as

Patient-Specific ModelingAdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalDose-Response Relationship, RadiationFemaleHumansLymphoma, Non-HodgkinMaleMiddle AgedRadioimmunotherapyRadiotherapy DosageRadiotherapy Planning, Computer-AssistedTomography, Emission-Computed, Single-PhotonBiomarkers, TumorbiomarkersdosimetryI-131non-Hodgkin lymphomaoutcomeradioimmunotherapy

Identifiers

PMID29083933
PMCPMC5695749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.